نتایج جستجو برای: نرمافزار ees

تعداد نتایج: 1978  

2012
Takeshi Kimura Masahiro Natsuaki Hiroki Shiomi Keiichi Igarashi Kengo Tanabe Takashi Akasaka Yoshiki Takatsu Masashi Iwabuchi

Background—Several recent randomized trials comparing everolimus-eluting stent (EES) and sirolimus-eluting stent (SES) reported similar outcomes. However, only 1 trial was powered for a clinical end point, and no trial was powered for evaluating target-lesion revascularization. Methods and Results—Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial is a prospective ...

2012
Tullio Palmerini Ajay J. Kirtane Letizia Bacchi Reggiani Hyo-Soo Kim Antoinette De Waha

Background—Some but not all studies have reported reduced rates of stent thrombosis (ST) with everolimus-eluting stents (EES) compared with other drug-eluting stents (DES). All of these studies were insufficiently powered to reliably detect differences in ST. We therefore performed a meta-analysis of randomized controlled trials comparing the risk of 2-year definite ST between EES and other DES...

Journal: :Journal of the American College of Cardiology 2009
Yoshinobu Onuma Neville Kukreja Nicolo Piazza Jannet Eindhoven Chrysafios Girasis Lisanne Schenkeveld Ron van Domburg Patrick W Serruys

OBJECTIVES The purpose of this study was to investigate the impact of everolimus-eluting stents (EES) in comparison with bare-metal stents (BMS), sirolimus-eluting stents (SES), and paclitaxel-eluting stents (PES) on the 6-month clinical outcomes in an all-comer population. BACKGROUND EES have been shown to be effective in the context of randomized trials with selected patients. The effect of...

2016
Pravesh Kumar Bundhun Manish Pursun Abhishek Rishikesh Teeluck Man-Yun Long

Controversies still exist with the use of Everolimus-Eluting Stents (EES) compared to other Drug-Eluting Stents (DES) in patients with Type 2 Diabetes Mellitus (T2DM). Therefore, in order to solve this issue, we aim to compare the 1-year adverse clinical outcomes between EES and non-EE DES with a larger number of patients with T2DM.Medline, EMBASE, PubMed databases, as well as the Cochrane libr...

Journal: :Circulation journal : official journal of the Japanese Circulation Society 2009
Ae Young Her Jong-Youn Kim Eui-Young Choi Sung-Ai Kim Rhee Sang Jae Chi Young Shim Seok-Min Kang Jong-Won Ha Namsik Chung

BACKGROUND Whether echo-Doppler-derived index of ventricular elastance or ventriculoarterial interaction can reliably reflect circulatory efficiency in various conditions was investigated in the present study and whether they can be helpful in predicting exercise capacity in patients with dilated cardiomyopathy (DCM). METHODS AND RESULTS The 25 patients with DCM, 25 age- and gender-matched hy...

Journal: :Journal of the American College of Cardiology 2012
Renato Valenti Angela Migliorini Guido Parodi Nazario Carrabba Ruben Vergara Emilio V Dovellini David Antoniucci

OBJECTIVES The goal of this study was to compare the outcomes of patients treated with everolimus-eluting stents (EES) with outcomes of patients treated with first-generation paclitaxel-eluting stents (PES) for unprotected left main disease (ULMD). BACKGROUND No data exist about the comparison of these 2 types of stents in ULMD. METHODS The primary endpoint of the study was a 1-year composi...

2013
Ung Kim Chan-Hee Lee Jung-Hwan Jo Hyun-Wook Lee Yoon-Jung Choi Jang-Won Son Sang-Hee Lee Jong-Seon Park Dong-Gu Shin Young-Jo Kim Myung-Ho Jeong Myung-Chan Cho Jang-Ho Bae Jae-Hwan Lee Tae-Soo Kang Kyung-Tae Jung Kyung-Ho Jung Seung-Wook Lee Jang-Hyun Cho Won Kim Seung-Ho Hur Ki-Sik Kim Heon-Sik Park Moo-Hyun Kim Jin-Yong Hwang Doo-Il Kim Tae-Ik Kim

We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven t...

Journal: :Circulation. Cardiovascular interventions 2012
Wail Nammas

BACKGROUND Some but not all studies have reported reduced rates of stent thrombosis (ST) with everolimus-eluting stents (EES) compared with other drug-eluting stents (DES). All of these studies were insufficiently powered to reliably detect differences in ST. We therefore performed a meta-analysis of randomized controlled trials comparing the risk of 2-year definite ST between EES and other DES...

2014
M. A. Velders A. J. van Boven J. Brouwer P. C. Smits A. W. J. van ’t Hof C. J. de Vries M. Queré S. H. Hofma

AIMS Everolimus-eluting stents (EES) were superior to sirolimus-eluting stents (SES) in a dedicated myocardial infarction trial, a finding that was not observed in trials with low percentages of ST-elevation myocardial infarction (STEMI). Therefore, this study sought to investigate the influence of clinical presentation on outcome after EES and SES implantation. METHODS A pooled population of...

2018
Diego A Arroyo Sara Schukraft Zacharenia Kallinikou Jean-Christophe Stauffer Gérard Baeriswyl Jean-Jacques Goy Mario Togni Stéphane Cook Serban Puricel

Aims To compare endothelium-dependent vasomotor function and vascular healing 15 months after implantation of two new-generation drug-eluting stents and biovascular scaffolds (BVS). Methods and results A total of 28 patients previously treated with a SYNERGY stent (bioabsorbable polymer everolimus-eluting stents (BP-EES)), a PROMUS stent (persistent polymer everolimus-eluting stents (PP-EES))...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید